Consistency of Product Quality for SB5, an Adalimumab Biosimilar

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource, 1 online resource.

Language: Englisch

Bibliographic citation: Consistency of Product Quality for SB5, an Adalimumab Biosimilar ; volume:37 ; number:2 ; day:31 ; month:1 ; year:2023 ; pages:271-277 ; date:3.2023
BioDrugs ; 37, Heft 2 (31.1.2023), 271-277, 3.2023

Creator: Lee, JongAh Joanne
Lee, Nayoung
Seo, Young Jun
Kim, Ilkoo

Contributor: SpringerLink (Online service)

DOI: 10.1007/s40259-023-00581-x

URN: urn:nbn:de:101:1-2023101922144165446249

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lee, JongAh Joanne
Lee, Nayoung
Seo, Young Jun
Kim, Ilkoo
SpringerLink (Online service)

Other Objects (12)

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Consistency of Product Quality for SB5, an Adalimumab Biosimilar

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

AVT02: An Adalimumab Biosimilar

Correction to: AVT02: An Adalimumab Biosimilar

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab

Relevance of Adalimumab Product Attributes to Patient Experience in the Biosimilar Era: A Narrative Review

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab

Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh

Related objects

Reset password